Is PTC Therapeutics, Inc. (PTCT) a good stock to buy?

Olyth's institutional analysis of PTCT reveals an Altman Z-Score of 1.77 and a Piotroski F-Score of 6/9. These metrics, combined with its 5-year revenue trend ($1.73B most recent), help investors decide if PTCT fits their risk profile.

What is the current P/E ratio for PTCT?

As of the latest trading session, PTC Therapeutics, Inc. (PTCT) has a trailing P/E ratio of 8.13.

Who is the CEO of PTC Therapeutics, Inc.?

The current Chief Executive Officer of PTC Therapeutics, Inc. is Matthew Klein.

What was PTCT's revenue for the last 5 years?

According to its latest income statements, PTC Therapeutics, Inc. reported annual revenues of $1.73B (2025), $0.81B (2024), $0.94B (2023), $0.70B (2022), $0.54B (2021) respectively.

Does PTCT pay a dividend?

PTC Therapeutics, Inc. does not currently pay a dividend to its shareholders.

How much debt and cash flow does PTCT have?

In its latest reporting period, PTC Therapeutics, Inc. generated $0.70B in Free Cash Flow against a total debt load of $0.49B.

What is the Price-to-Book (P/B) ratio of PTC Therapeutics, Inc.?

The Price-to-Book (P/B) ratio for PTC Therapeutics, Inc. (PTCT) is currently -27.05.

What is the Price-to-Sales (P/S) ratio of PTCT?

Based on trailing twelve-month data, PTC Therapeutics, Inc. (PTCT) trades at a Price-to-Sales (P/S) ratio of 3.29.

What is PTC Therapeutics, Inc.'s Return on Equity (ROE)?

PTC Therapeutics, Inc. (PTCT) has a Return on Equity (ROE) of -362.44%, representing its profitability relative to shareholder equity.

PTCT

PTC Therapeutics, Inc. · Healthcare

68.82

0.12%(-0.08)

Market Open

Last Updated: — ET

52W L: $35.9552W H: $87.50

$68.96

CHG+7.15 (+11.57%)

H$70.92

L$60.83

VOL17M

PTCT (1h)

Company Profile

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Sector

Healthcare

Industry

Biotechnology

Employees

939

IPO Date

2013-06-20

Beta

0.55

Websitewww.ptcbio.com↗

PTCT

PTC Therapeutics (NASDAQ:PTCT) EVP Lee Scott Golden Sells 829 Shares

Phocas Financial Corp. Has $1.94 Million Stock Position in PTC Therapeutics, Inc. $PTCT

Neil Gregory Almstead Sells 52,003 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. $PTCT Shares Sold by Assenagon Asset Management S.A.

PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors

Critical Contrast: PTC Therapeutics (NASDAQ:PTCT) & Axsome Therapeutics (NASDAQ:AXSM)